Yahoo
NasdaqCM - Nasdaq Real Time Price USD

China SXT Pharmaceuticals, Inc. (SXTC)

3.6800 +0.1300 (+3.66%)
At close: October 28 at 4:00:00 PM EDT
3.5200 -0.1600 (-4.35%)
Pre-Market: 4:52:59 AM EDT
Chart Range Bar
Loading chart for SXTC
  • Previous Close 3.5500
  • Open 3.8100
  • Bid 3.6000 x 100
  • Ask 3.6600 x 100
  • Day's Range 3.4601 - 3.8297
  • 52 Week Range 3.2800 - 8,376,000.0000
  • Volume 168,487
  • Avg. Volume 219,333
  • Market Cap (intraday) 381,156
  • Beta (5Y Monthly) 1.86
  • PE Ratio (TTM) --
  • EPS (TTM) -73,040.0000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

www.sxtchina.com

56

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SXTC
100.00%
S&P 500 (^GSPC)
13.13%

1-Year Return

SXTC
100.00%
S&P 500 (^GSPC)
12.38%

3-Year Return

SXTC
100.00%
S&P 500 (^GSPC)
88.08%

5-Year Return

SXTC
100.00%
S&P 500 (^GSPC)
68.48%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -15.78%

  • Return on Equity (ttm)

    -27.49%

  • Revenue (ttm)

    1.14M

  • Net Income Avi to Common (ttm)

    -6.21M

  • Diluted EPS (ttm)

    -73,040.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.32M

  • Total Debt/Equity (mrq)

    3.77%

  • Levered Free Cash Flow (ttm)

    -4.74M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: